Navigation Links
Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron

BILLERICA, Massachusetts --- June 20, 2007 --- Millipore Corporation today announced the release of new data concerning its ReNcell neural stem cell lines. The research was conducted by the Department of Physiology at University College London and ReNeuron Group plc, whose ReNcell distribution agreement with Millipore was announced in 2006. The data will be presented by Dr. Vi Chu, research & development scientist for Millipore’s Bioprocess Division, in a technology talk at the ISSCR meeting in Cairns, Australia on June 20, 2007.

The data conclude that the ReNcell lines, ReNcell VM and ReNcell CX, will continuously expand in monolayer culture. Both cell lines have the ability to differentiate into neurons, astrocytes and oligodendrocytes, and the researchers were able to differentiation the ReNcell VM line into electrophysiologically active dopaminergic neurons. The study was published in the May edition of BMC Neuroscience and may be read in its entirety at:

The ReNcell neural stem cell lines are immortalized human neural progenitor cells that have the ability to readily differentiate into neural cell types and will replicate indefinitely. ReNcell immortalized cells display the same marker patterns as normal cells and are able to grow and remain stable after culturing. These cells are important tools for the discovery of new therapies targeting diseases of the central nervous system.

Millipore’s Bioscience Division provides innovative tools, services and biological reagents that drive advancements in biomedical and academic research as well as support the discovery and development of new pharmaceuticals. The product portfolio has been further enhanced with the 2006 addition of Chemicon, Upstate and Linco product lines, allowing Millipore to provide the most complete offering of life science tools on the market. Our customers work in leading research laboratories across a variety of industries throughout the world. Millipore improves their laboratory productivity and efficiency through optimized workflows. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit


About Millipore

Millipore is a leading provider of products and services that improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The Company is organized in two operating divisions. Its Bioprocess Division helps enables pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its Bioscience division helps to optimize laboratory productivity and workflows. Its products and enabling technologies that are used in the laboratory are esse ntial for the research and development of biologically based life science therapeutics. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide. For additional information on Millipore Corporation, please visit its website at:

About ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. The Group has also leveraged their stem cell technologies into non-therapeutic areas such as drug discovery. ReNeuron was founded in 1997 to commercialize technology discovered by its founding scientists working at the Institute of Psychiatry, Kings College London. ReNeuron currently employs around 30 staff, including 15PhDs, with many years combined experience in stem cell research and development. ReNeuron operates form state-of-the-art laboratories in Guildford, Surrey, UK, which are fitted out to meet the stringent requirements of the regulatory authorities for cell therapy products. For additional information on ReNeuron, please visit its website at:

Millipore is a registered trademark of Millipore Corporation. ReNcell is a registered trademark of ReNeuron Group plc.

Media Contact:

Lauren Nolan

Communications Specialist

Millipore Corporation



Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... for oncology and hematology continuing medical education (CME), today announced that the first ... Grand Hyatt New York. , “The prevention, detection and treatment of gastrointestinal cancers ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and physical therapies ... with innovative technologies and under the right circumstances, these practices can be merged. ... a dual-approach to his or her therapeutic sessions, as well as gives the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... 7th Annual 2015 Golden Bridge Business Awards under the New Products and Services ... capex web based sample management software that helps labs organize data ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric breast ... focus of numerous abstracts accepted for presentation here, at the 101st Annual Radiology ... highlight the use of Volpara Solutions’ quantitative breast imaging software tools for providing ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
Breaking Medicine News(10 mins):